Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

Vaccine

Volumn 20, Issue 1-2, 2001, Pages 218-225

  Plante, Martin ^a   Jones, Taff ^a   Allard, Francine ^a   Torossian, Krikor ^a   Gauthier, Joelle ^a   St Félix, Noutcheka ^a   White, Greg L ^a   Lowell, George H ^a   Burt, David S ^a  

^a Intellivax International Inc   (Canada)

Author keywords

Influenza; Nasal immunization; Proteosomes; Vaccine

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; INJECTION; LUNG LAVAGE; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROVOCATION TEST; TITRIMETRY;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CYSTEINE ENDOPEPTIDASES; CYTOKINES; DRUG EVALUATION, PRECLINICAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MULTIENZYME COMPLEXES; ORTHOMYXOVIRIDAE INFECTIONS; PROTEASOME ENDOPEPTIDASE COMPLEX; TH1 CELLS; TH2 CELLS; VACCINATION; VACCINES, SUBUNIT; VEHICLES;

EID: 0035850955     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00268-7     Document Type: Article

References (50)

1. Intranasal influenza vaccine: Adding to the armamentarium for influenza control
2. A method for timely assessment of influenza-associated mortality in the United States
3. Pneumonia and influenza deaths during epidemics: Implications for prevention
4. Influenza: Its control in persons and populations
5. Effect of vaccination of a school-age population upon the course of an A2/Hong Kong influenza epidemic
6. Influenza and pneumococcal vaccination levels among adults >65 years
7. Is there a role for a mucosal influenza vaccine in the elderly?
8. Influenza vaccination in 22 developed countries: An update to 1995
9. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial
10. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children: A multicentered evaluation of dosage and safety
11. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature
12. Influenza
13. Influenza vaccine: A reappraisal of their use
14. Influenza
15. Proteosomes for improved nasal, oral or injectable vaccines
16. Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection
17. Specific immunity in influenza - Summary of Influenza Workshop III
18. Determinants of immunity to influenza infection in man
19. The common mucosal immune system and current strategies for induction of immune responses in external secretions
20. Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract
21. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity
22. Antibody responses and interferon titers in the respiratory tracts of mice after aerosolized exposure to influenza virus
23. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus
24. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: Role in protection against influenza A in mice
25. Immunity to influenza A virus infection in young children: A comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine
26. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity
27. The systemic and mucosal immune response of humans to influenza A virus
28. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine
29. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children]
30. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
31. Type 1/type 2 immunity in infectious diseases
32. Inflammatory responses in influenza A virus infection
33. Influenza pathogenesis defence mechanisms
34. Mechanisms of viral clearance and persistence
35. Mucosal vaccines for the prevention of influenza
36. Intranasal administration of influenza vaccines
37. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: A review
38. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults
39. Estimation of the efficacy of live, attenuated influenza vaccine from a 2-year, multicenter vaccine trial: Implications for influenza epidemic control
40. Effectiveness of live attenuated intranasal influenza virus vaccine in healthy working adults
41. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses
42. Approaches to improved influenza vaccination
43. Immunity to influenza in the elderly
44. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials
45. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly
46. Developments in mucosal influenza virus vaccines
47. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory
48. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: Correlation with serum and local antibodies
49. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high risk subjects
50. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults